Pharmacological management of obesity: an Endocrine Society clinical practice guideline
Key Products: Trevogrumab, anti-myostatin antibody designed to preserve lean muscle mass that was tested in combination with semaglutide to offset GLP-1-associated muscle loss
Other strategies to manage side effects include: Eating smaller, more frequent meals rather than large portions Avoiding high-fat, greasy, or spicy foods that may exacerbate nausea Staying well-hydrated , particularly if experiencing vomiting or diarrhoea Gradually escalating the dose as prescribed, allowing your body time to adjust When to seek medical advice : Contact your GP or diabetes care team promptly if you experience severe or persistent vomiting that prevents adequate fluid intake, signs of dehydration, severe abdominal pain (which could indicate pancreatitis or gallbladder problems), or jaundice
As of now, Eliquis has been approved to reduce risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF), for treatment of prophylaxis of DVT, and for treament of pulmonary embolism (PE)
Enhances Insulin Sensitivity: GLP-1 improves insulin sensitivity, particularly in muscle tissue, allowing cells to utilize glucose more efficiently for energy rather than storing it as fat
